Grace Therapeutics (GRCE) AI Stock Analysis

• Market Cap: $57.72M
• Dividend Yield: N/A
• Average Volume (3M): 58.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: N/A
• EPS Growth: 45.97%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 15,474,026
• 10 Day Avg. Volume: 55,886
• 30 Day Avg. Volume: 58,559
• PEG Ratio: 0.05
• Price to Book (P/B): 0.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.85
• Enterprise Value/Market Cap: 0.53
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -3.77
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: $3.50 ▼(-7.89% Downside)

The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and negative free cash flow). Offsetting factors include constructive technical trend and meaningful positive corporate catalysts (NDA accepted with PDUFA date, positive Phase 3 outcome, extended IP, and incremental financing). Valuation remains pressured by negative earnings and no dividend support.

Positive Factors

Cash Management

Effective cash management ensures operational continuity and supports ongoing R&D activities, crucial for a biotech firm aiming to bring new therapies to market.

Strong Equity Base

A strong equity base provides financial stability and reduces risk, allowing the company to focus on long-term R&D and strategic initiatives without immediate debt pressures.

Regulatory Progress

The FDA's acceptance of the NDA for GTx-104 indicates potential future revenue streams and validates the company's R&D efforts, enhancing its market position in treating aSAH.

Negative Factors

Cash Flow Challenges

Ongoing cash burn poses a risk to financial sustainability, necessitating strategic financial management to secure funding and support long-term growth.

Operational Losses

Persistent operational losses highlight inefficiencies and the need for strategic management to achieve profitability, impacting long-term financial health.

No Revenue Generation

The lack of revenue generation is concerning as it challenges the company's ability to sustain operations and fund future R&D without external financing.

Grace Therapeutics Business Overview & Revenue Model

Company Description

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.

How the Company Makes Money

Grace Therapeutics makes money primarily through the development and commercialization of its proprietary therapeutic products. The company generates revenue by selling its approved drugs to healthcare providers, hospitals, and specialty pharmacies. Key revenue streams include product sales, licensing agreements, and strategic partnerships with other pharmaceutical companies. These partnerships often involve collaboration on research and development efforts, as well as co-marketing and distribution agreements that expand the reach of Grace's products. Additionally, the company may receive milestone payments and royalties from out-licensed products and technologies that are successfully commercialized by its partners.

Grace Therapeutics Financial Statement Overview

Summary

Grace Therapeutics faces significant challenges with no revenue and persistent losses, raising sustainability concerns. The strong equity base and lack of debt provide some support, but the cash flow situation necessitates strategic financial management to secure future funding and ensure operational viability.

Income Statement

Grace Therapeutics shows no revenue generation over the past periods, which is concerning for financial health. The consistent negative EBIT and EBITDA margins indicate ongoing operational losses. The absence of revenue growth further exacerbates the situation, reflecting challenges in product development or market penetration.

Balance Sheet

The company maintains a strong equity position, with a favorable equity ratio above 85% in the latest TTM. The absence of debt reduces financial risk, but the declining total assets and equity could indicate potential liquidity pressures in the future.

Cash Flow

Negative operating and free cash flows highlight ongoing cash burn, typical in early-stage biotech firms. However, cash reserves have been managed to cover short-term needs, albeit with decreasing cash flow from financing activities, suggesting potential funding challenges ahead.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	196.00K
Gross Profit	0.00	0.00	-11.00K	0.00	0.00	120.00K
EBITDA	-8.11M	-16.67M	-14.62M	-18.12M	-15.34M	-9.79M
Net Income	-7.82M	-9.57M	-12.85M	-42.43M	-9.82M	-19.68M
Balance Sheet
Total Assets	66.58M	71.99M	73.30M	79.12M	128.62M	62.46M
Cash, Cash Equivalents and Short-Term Investments	16.86M	22.13M	23.00M	27.89M	43.66M	60.73M
Total Debt	0.00	0.00	0.00	485.00K	295.00K	86.00K
Total Liabilities	3.76M	5.38M	11.56M	11.17M	20.35M	6.80M
Stockholders Equity	62.82M	66.61M	61.74M	67.95M	108.27M	55.66M
Cash Flow
Free Cash Flow	-12.02M	-14.90M	-12.36M	-15.93M	-17.23M	-14.39M
Operating Cash Flow	-12.02M	-14.90M	-12.33M	-15.91M	-17.23M	-14.32M
Investing Cash Flow	15.00K	0.00	104.00K	13.15M	-3.52M	-9.86M
Financing Cash Flow	13.71M	14.03M	7.36M	304.00K	0.00	59.49M

Grace Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRCE, the sentiment is Positive. The current price of 3.8 is above the 20-day moving average (MA) of 3.45, above the 50-day MA of 3.26, and above the 200-day MA of 3.00, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 74.59 is Negative, neither overbought nor oversold. The STOCH value of 73.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRCE.

Grace Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GRCE	58 Neutral	$57.72M	-6.50	-13.15%	―	―	45.97%
PYPD	56 Neutral	$75.83M	-1.56	-390.53%	―	―	61.23%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INKT	48 Neutral	$59.22M	-4.09	―	―	―	21.48%
CVKD	46 Neutral	$17.44M	-0.98	-468.03%	―	―	-9.80%
ALGS	42 Neutral	$59.38M	-0.52	-141.82%	―	-55.88%	6.14%
GBIO	39 Underperform	$36.86M	-0.59	-80.81%	―	-17.82%	57.32%

Grace Therapeutics Corporate Events

Grace Therapeutics Announces Q2 2026 Financial Results

On November 13, 2025, Grace Therapeutics announced its second quarter 2026 financial results and business updates, highlighting the FDA’s acceptance for review of its New Drug Application (NDA) for GTx-104, with a PDUFA target date set for April 23, 2026. The company’s Phase 3 STRIVE-ON trial showed positive outcomes for GTx-104, and a new U.S. patent was granted for its IV dosing regimen, extending intellectual property protection to 2043. Financially, the company reported a net loss reduction due to decreased R&D expenses and secured additional funding through warrant exercises, estimating cash and cash equivalents at $20 million as of October 31, 2025.

The most recent analyst rating on (GRCE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Grace Therapeutics stock, see the GRCE Stock Forecast page.

Grace Therapeutics Secures $4M Through Warrant Exercise

On October 23, 2025, Grace Therapeutics announced it secured approximately $4.0 million in additional funding through the exercise of common warrants initially issued in a 2023 private placement. This development follows the FDA’s acceptance of the company’s New Drug Application for GTx-104, a novel injectable formulation of nimodipine for treating aneurysmal subarachnoid hemorrhage. The FDA has set a target review date of April 23, 2026, for the application. This funding and FDA progress are significant for Grace Therapeutics, potentially enhancing its market positioning and offering new treatment options for aSAH patients.

The most recent analyst rating on (GRCE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Grace Therapeutics stock, see the GRCE Stock Forecast page.